Grand Prize Winner in $1.75M Water Abundance XPRIZE Announced at XPRIZE Visioneering 2018
During Visioneering 2018, XPRIZE’s annual gathering of philanthropists and innovators to evaluate concepts for future competitions, the Foundation revealed the results of its latest, completed XPRIZE. The Skysource / Skywater Alliance was announced as the grand prize winner of the $1.75M Water Abundance XPRIZE, a two-year competition aimed at alleviating the global water crisis with energy-efficient technologies that harvest fresh water from thin air. In addition at Visioneering, five new prize concepts were evaluated with top honors going to a prize concept called “Coral Survival”, a prize designed to protect and restore coral reefs. This prize will move forward into the XPRIZE pipeline.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181022005795/en/
The Skysource / Skywater Alliance team, based in Venice Beach, California, wins the Water Abundance XPRIZE (Photo: Business Wire)
The Water Abundance XPRIZE, powered by the Tata Group and Australian Aid, was launched in 2016 at the United Nations in New Delhi. The Skysource / Skywater Alliance, based in Venice Beach, California, received a grand prize of $1.5M for developing an easily deployable high-volume water generator that can be used in any climate, meeting the competition parameters of extracting a minimum of 2,000 liters of water per day from the atmosphere using 100 percent renewable energy, at a cost of no more than two cents per liter. A second team, JMCC WING, based in South Point, Hawaii, received a $150K prize to acknowledge the team's ingenuity in developing a unique technological approach.
“This year’s Visioneering beautifully encapsulates the full life-cycle of an XPRIZE with the awarding of the Water Abundance XPRIZE, which began as a prize concept proposed at a Visioneering just five years earlier by our trustee, Eric Hirshberg,” said Dr. Peter H. Diamandis, XPRIZE founder and executive chairman. “It is testament to the basic premise that Visioneering is the forum where participants’ breakthrough ideas are presented, evaluated, upvoted, funded and then go on to have real-world, transformative impact.”
In addition, attendees of Visioneering deemed a “Coral Survival” prize concept, whose development efforts were sponsored by Wendy Schmidt, as the top prize design. This prize design, once funded, will launch as a future XPRIZE competition. The prize concept calls for innovations that can scale coral survival 1,000-fold, taking the survival rate of new coral larvae from 1 in 1 million, to 1 in 1 thousand, helping us to replenish our rapidly dying coral reefs.
“What particularly resonated about the coral reef presentation is the urgency with which we need to address this important issue caused by climate change before it is too late. We are committed to finding the necessary funds to capitalize and launch this competition as soon as possible,” said Anousheh Ansari, XPRIZE chief executive officer. “We are incredibly proud of the hard work done by all of the teams who designed this year’s prize concepts over the past several months and are grateful to our visionary sponsors, especially Wendy Schmidt, who underwrote the development of these prize concepts and whose visions for a positive future align with that of XPRIZE.”
The annual XPRIZE Visioneering convenes a select group of CEOs, world leaders, philanthropists, and other experts for three days to evaluate, prioritize and fund competition designs. Additional prize concepts presented at Visioneering 2018 were in the areas of: Off-Grid Energy Access, sponsored by Kingo; Natural Disaster Prediction, sponsored by Fairfax Financial Holdings; Lifting Farmers Out of Poverty, sponsored by Gagan Gupta; and Feeding the Next Billion, sponsored by The Tony Robbins Foundation and Foundation for Food and Agriculture Research.
For more information on Visioneering, please visit https://www.xprize.org/visioneering.
For more information on the Water Abundance XPRIZE, visit https://water.xprize.org/.
XPRIZE, a 501(c)(3) nonprofit, is the global leader in designing and implementing innovative competition models to solve the world’s grandest challenges. Active competitions include the Lunar XPRIZE, the $20M NRG COSIA Carbon XPRIZE, the $15M Global Learning XPRIZE, the $10M ANA Avatar XPRIZE, the $7M Shell Ocean Discovery XPRIZE, the $7M Barbara Bush Foundation Adult Literacy XPRIZE, and the $5M IBM Watson AI XPRIZE. For more information, visit www.xprize.org.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Illumina and the Lundbeck Foundation GeoGenetics Centre Collaborate to Generate One of the Largest Ancient Genome Datasets to Decode the Genetic Origins and Evolution of Mental Health Issues26.3.2019 09:00:00 EET | Tiedote
Illumina (NASDAQ:ILMN) and the Lundbeck Foundation GeoGenetics Centre at the University of Copenhagen, Denmark partner to explore the relationship between the evolutionary history of select mental and neurological disorders and infectious pathogens. One of the first projects of its kind worldwide, the endeavor aims to acquire new knowledge in terms of the medical and biological understanding of special factors underlying the development of human neuropsychiatric diseases through the ages. Ultimately, the project may provide a new approach to the development of medicines and other therapeutic treatments for mental and neurological conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190325005867/en/ Where do brain disorders come from? In an effort to shed light on the role of microbes in the pathogenesis of neuropsychiatric illnesses, such as Alzheimer’s disease and schizophrenia, Professor Eske Willerslev and his team
Earth Networks Announces Completion of Severe Weather Early Warning System for PAGASA26.3.2019 02:00:00 EET | Tiedote
Earth Networks announced today the completion of the Philippines’ first nationwide severe weather monitoring and alerting network with associated software services for the Philippine Atmospheric, Geophysical, and Astronomical Services Administration (PAGASA), the National Meteorological and Hydrological Services (NMHS) agency of the Republic of the Philippines. The announcement was made at the 6th annual InterMET Asia conference in Singapore. Initiated in 2017, and formally commissioned this week, the technology partnership between PAGASA and Earth Networks is the first of its kind in the Philippines and surrounding regions, powered by a network of total lightning sensors and real-time automatic weather stations for mesoscale monitoring. Installed and operated together with Philippines partner West Point Engineering, the 10-year program includes: Real-time lightning detection powered by the Earth Networks Total Lightning Network On-the-ground weather monitoring via the Earth Networks W
Game of Thrones Winter is Coming™ Launches Worldwide26.3.2019 02:00:00 EET | Tiedote
Yoozoo Games, a leading game developer and publisher, today announced the global launch of Game of Thrones Winter is Coming™ , a real-time strategy PC browser game officially licensed by Warner Bros. Interactive Entertainment under license from HBO®. The game is now available in English, with additional languages to follow. HBO, Warner Bros. Interactive Entertainment and Yoozoo Games have collaborated to recreate Westeros on a massive scale, delivering an authentic and immersive multiplayer world laid out across the Seven Kingdoms – complete with major landmarks and castles from the epic TV series. The story begins immediately following the death of Eddard Stark, when the player emerges as a new Westeros lord or lady in his stead. Strategising starts in earnest in Game of Thrones Winter is Coming as players aim to build an impenetrable base, train a victorious army and recruit faithful followers from a pool of iconic characters. As players progress, they must continue to acquire the mi
bluebird bio Statement on European Regulatory Status of LentiGlobin™26.3.2019 01:40:00 EET | Tiedote
A third party press release was issued today stating that the EMA (European Medicines Agency) issued an approval for the conditional Marketing Authorization Application (MAA) for LentiGlobin™, bluebird bio’s investigational gene therapy for the treatment of transfusion dependent β-thalassemia (TDT). LentiGlobin for TDT is scheduled to be reviewed as part of the CHMP (Committee on Human Medicinal Products) meeting from March 25 – 28, however no opinion has been issued by the CHMP. If the CHMP’s opinion is issued it would then be reviewed by the European Commission (EC), which has the authority to grant approval for the use of LentiGlobin in the EU. About bluebird bio, Inc. bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working
Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis25.3.2019 23:30:00 EET | Tiedote
Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for ozanimod for the treatment of adults with relapsing forms of multiple sclerosis (RMS). Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator, which binds with high affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5). The pivotal efficacy and safety data provided in the application result from the SUNBEAM™ and RADIANCE™ Part B phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled trials. “New oral treatment options with differentiated profiles like ozanimod are needed to help address an unmet need for people with relapsing forms of MS,” said Jay Backstrom, M.D., Chief Medical Officer for Celgene. “With concurrent applications in the U.S. and EU, we look forward to advancing this promising medicine through the regulatory review process to provide a new option for the treatment of RMS in
AVLT and UKTS Announce the European Medicines Agency’s Approval of the Conditional Marketing Authorization Application for Zynteglo™ (Previously Known as Lentiglobin™) Gene Therapy for the Treatment of Transfusion Dependent Beta Thalassaemia25.3.2019 22:50:00 EET | Tiedote
Associazione Veneta Lotta alla Talassemia (AVLT) and the UK Thalassaemia Society (UKTS) announced today that the European Medicines Agency (EMA) has approved bluebird bio’s application for Conditional Marketing Authorization (cMAA) of their product Zynteglo™, a gene therapy for the treatment of adolescents and adults with transfusion-dependent β-thalassaemia (TDT) who do not have a β0/β0 genotype. As a result of this marketing authorisation, Zynteglo™ is now approved for use in all European countries covered by the European Medicines Agency. Zynteglo™ has been given ‘conditional authorisation’. This means that there is more evidence to be submitted, which the company is required to provide under specific obligations. Every year, the EMA will review any new information that becomes available. “People living with transfusion-dependent β-thalassaemia have a reduced life expectancy, requiring life-long frequent blood transfusions that are life-saving but may lead to complications, includin
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme